Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/sLBkhMrCDsgLmlDkSu

Top Story

Myeloma in the News

Celgene to present myeloma trial data at ASH meeting
Celgene announced it will present data from more than 200 recent and ongoing clinical trials, including those for multiple myeloma, at the American Society of Hematology annual meeting next month. Read the release.

Onyx to present carfilzomib studies at ASH meeting
Onyx Pharmaceuticals announced almost 20 presentations evaluating carfilzomib and ONX 0803 in hematological cancers -- including four oral and seven poster presentations on the carfilzomib development program in patients with relapsed and refractory multiple myeloma -- to be presented at the 51st American Society of Hematology Annual Meeting next month. American City Business Journals/PRNewswire (11/10)

ASH elects new officers to Executive Committee
The American Society of Hematology has elected new officers to its Executive Committee, to begin serving in January 2010. They include Armand Keating, M.D., Marilyn J. Telen, M.D., Kenneth C. Anderson, M.D., and Mohandas Narla, DSc. Reuters/PRNewswire (11/3)

NHS Scotland approves Velcade for wider range of patients
The Scottish Medicines Consortium has approved the use of Velcade within NHS Scotland as a monotherapy for progressive myeloma in patients at first relapse from their front line therapy who have already undergone or are not candidates for bone marrow transplantation. Read the release.

Research Updates

Blood. 2009 Oct 27
How I treat multiple myeloma in younger patients
Stewart AK, Richardson PG, San-Miguel JF.

Blood. 2009 Oct 30
A randomized phase III study on the effect of thalidomide combined with Adriamycin, dexamethasone (TAD), and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnege H, van Marwijk-Kooy M, Joosten P, Minnema MC, Ammerlaan R, Sonneveld P.

Blood. 2009 Nov 2
Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroupe Francophone du Myelome (IFM)
Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pegourie B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M.

Clin Lymphoma Myeloma. 2009 Oct
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment
Li J, Zhou DB, Jiao L, Duan MH, Zhang W, Zhao YQ, Shen T.

Clin Lymphoma Myeloma. 2009 Oct
Kyphoplasty for patients with multiple myeloma is a safe surgical procedure: results from a large patient cohort
Huber FX, McArthur N, Tanner M, Gritzbach B, Schoierer O, Rothfischer W, Krohmer G, Lessl E, Baier M, Meeder PJ, Kasperk C.

Expert Rev Anticancer Ther. 2009 Nov
Lenalidomide in multiple myeloma
Sirohi B, Powles R.

J Clin Oncol. 2009 Oct 26
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF.

Leukemia. 2009 Oct
Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!
Mohty M.

News from MMRF

Perfect holiday gifts -- MMRF Acorn Jewelry
With the holidays quickly approaching, there is no better time than now to place your order for pieces from the MMRF's exclusive Acorn Jewelry Collection. Whether you are looking for something special for Thanksgiving, Christmas, Hanukkah, birthdays, weddings or other special occasions, our jewelry is a beautiful gift. Each is a symbol of hope for patients and families touched by multiple myeloma and, with every purchase supporting research, a meaningful way to support the MMRF's efforts to bring patients the next generation of treatments. Shop today!

MMRF Marathon and Half Marathon program passes $1M mark
The MMRF Marathon and Half Marathon program exceeded the $1 million mark with the NYC Marathon bringing in $600,000. The program's final 2009 event, the San Antonio Rock 'n Roll Marathon and Half Marathon will take place this weekend. The MMRF is deeply grateful to all of the runners and their supporters for helping to ensure our continued investment in new treatments for myeloma. Get information about the 2010 MMRF Powerful Athletes schedule and information here.

Learn more
about MMRF ->

About Myeloma | About MMRF | Donate | Get Involved | Medical Programs

Staying Informed

SmartQuote

I have learned to use the word 'impossible' with the greatest caution."

--Wernher von Braun,
German-American rocket scientist

Subscriber Tools

Search past news | Privacy policy

Editorial Team

Lead Editor: Kathryn Doherty


	Recent MMRF SmartBrief Issues: Thursday, October 29, 2009 Thursday, October 15, 2009 Thursday, October 01, 2009 Thursday, September 17, 2009 Thursday, September 03, 2009			Mailing Address: SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005